REGENERON - Eylea’s Litigation Settlement = Good Start to 2012!
Regeneron (REGN) settled its patent litigation with Genentech (Roche) over Eylea (VEGF Trap-Eye, L, partnered with Bayer for Ex-US) for US ophthalmic use. REGN will have non exclusive rights to all of the Davis-Smyth and other technology patents related to ophthalmic uses in US (Eylea) till May 16th 2016. In exchange REGN will pay make milestone and royalty payments to Roche -$60m when cumulative US sales of Eylea reach $400m + will pay royalties of 4.75% on US sales between $400m and $3b and rises to 5.5% on cumulative sales over $3b. We had already assumed damages earlier in our model, where we have also considered similar damage as ZALTRAP (aflibercept, PhIII, CRC, NSCLC, prostate), which contains …. For more details, please read our report released on 6th January, 2012 on Regeneron titled “Eylea’s Litigation Settlement = Good Start to 2012!”
COMPANIES MENTIONED
REGENERON
REGENERON
